Page 1

Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018


Summary: This report provides an overview of the pipeline landscape for pancreatic and bile duct cancer. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pancreatic and bile duct cancer, and features dormant and discontinued products. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas, a large gland situated in the abdominal cavity that is responsible for the secretion of digestive fluids and insulin. Signs and symptoms include upper abdominal pain, yellowing of the skin and the whites of the eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatments include surgery, chemotherapy and radiation therapy. There are 759 products in development for this indication. Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile ducts, a series of tubes in the biliary tract that are essential for the secretion of bile, which plays an important role in digestion. Symptoms include discomfort in the abdomen, loss of appetite, fevers and weight loss. Treatment includes chemotherapy and radiation therapy. There are 133 products in development for this indication. Molecular targets acted on by products in development for pancreatic and bile duct cancer include vascular endothelial growth factor receptors, programmed cell death protein 1 and signal transducer and activator of transcription 3. Companies operating in this pipeline space include Novartis, Eli Lilly and AstraZeneca. Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2312068 Scope: - Which companies are the most active within the pipeline for pancreatic and bile duct cancer? - Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication? - To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? - What are the most important R&D milestones and data publications to have happened within this field? Reasons to buy: - Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication - Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each


- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these - Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-beforebuying/2312068 Key Players:  3-V Biosciences Inc  4P-Pharma SAS  4SC AG  AB Science SA  AbbVie Inc  AbGenomics International Inc  Ability Pharmaceuticals SL  Aclaris Therapeutics Inc  Actuate Therapeutics Inc  Adamed Sp z oo  Aduro BioTech Inc  Advantagene Inc  Advenchen Laboratories LLC  Agios Pharmaceuticals Inc  AGV Discovery SAS  AIMM Therapeutics BV  Alissa Pharma  Alligator Bioscience AB  Allinky Biopharma  Altor BioScience Corp  Ambrx Inc  amcure GmbH  Amgen Inc  Amplia Therapeutics Pty Ltd  Anavex Life Sciences Corp  Andarix Pharmaceuticals Inc  ANP Technologies Inc  AntiCancer Inc  APEIRON Biologics AG  Apexigen Inc  Aphios Corp  Aposense Ltd  Ariad Pharmaceuticals Inc  ARMO Biosciences Inc


Continued‌ Get More Access about this Report@ http://www.orbisresearch.com/reports/index/pancreatic-andbile-duct-cancer-drug-development-pipeline-review-2018 About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients. Contact Info: Hector Costello Senior Manager – Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas - 75204, U.S.A. Phone No.: +1 (214) 884-6817; +912064101019 Email id: sales@orbisresearch.com

Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018  

This report provides an in-depth insight of Pancreatic and Bile Duct Cancer Drug Development Industry covering all important parameters incl...

Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018  

This report provides an in-depth insight of Pancreatic and Bile Duct Cancer Drug Development Industry covering all important parameters incl...

Advertisement